TheranosticTrials.org
Bringing Radioligand Therapy (RLT) Clinical Trials to Your Fingertips
Why TheranosticTrials.org?
The leading global platform for radiopharmaceutical & molecular imaging clinical trials
Global Reach
We are uniquely positioned at the heart of Theranostics.
Increasing Awareness
We're dedicated to increasing awareness about Theranostics and it's potential.
Fostering Engagement
We encourage active participation in the Theranostics community.
Building Connections
We connect physicians, clinics, and patients with Theranostic opportunities.
Comprehensive Resources
Access a complete list of cancer Theranostic Trials and educational materials.
Advancing the Field
We collaborate with key opinion leaders to push Theranostics forward.
Our Ultimate Goal
Provide more hope to cancer patients everywhere!
Navigating Tips
Pick Your Path
Stats
Distinguished Investigator
A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.
Geoffrey Johnson, MD
Geoffrey B. Johnson, M.D., Ph.D., is a Professor of Radiology, is board-certified in Radiology and Nuclear Medicine and recently rotated out of an 8-year tenure as Chair of Nuclear Medicine at Mayo Clinic. Under his leadership, Mayo Clinic in Rochester MN has become the largest theranostic center in the world, averaging 40 therapies per week for 2023. Dr. Johnson now serves as Associate Director of the Mayo Clinic Comprehensive Cancer Center (MCCCC) and as Chair of Radiopharmaceutical Therapy. Dr. Johnson is founder and Chief Scientific Officer of Nucleus RadioPharma, a CDMO for radiopharmaceutical development, production, and delivery. Dr. Johnson was the top-recruiting physician in the MCCCC in 2022 and has enrolled over 140 patients on radiopharmaceutical cancer therapy trials in the last 3 years, serving as overall PI and local PI. He also serves as Co-PI on multiple active theranostic trials. Dr. Johnson is a co-inventor of Alpha-PET Double-L.E.T. theranostic technologies, the first of which is now licensed to Perspective Therapeutics. Dr. Johnson served as Medical Director of the Nuclear Medicine Technology Program, Program Director of the Nuclear Radiology Fellowship Program and Chair of PET/MR research and development committee. Dr. Johnson earned his B.S. in chemical engineering at the Massachusetts Institute of Technology, receiving Tau Beta Phi academic honors. He completed his M.D./Ph.D. in the Mayo Medical-Scientist Training Program as the Davis Physician-Scientist Scholar. He completed postdoctoral training in immunology and surgery in the Mayo Graduate School. He went on to complete an internship in internal medicine, a residency in diagnostic radiology and a fellowship in nuclear radiology in Mayo School of Graduate Medical Education. In recognition of his work, Dr. Johnson has received awards and honors, including the Roentgen Resident Research Award and the twice the Honored Educator Award, conferred by the Radiological Society of North America; Physician/Scientist of the Year, conferred by Mayo School of Health Sciences; and the Carman Award for Excellence in Clinical Practice, conferred by the Department of Radiology, Mayo Clinic. Dr. Johnson is active in research and education, garnering more than 30 awards with trainees on projects at national and international meetings. Dr. Johnson’s memberships with 13 professional organizations include the AAI, ACR, ABR, ARRS, RSNA, ASNC, SNMMI and STR.
Read MoreRLT Components
RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.
There are several Components to a RLT that are simply demonstrated in the truck diagram including:
- Cancer Targets
- Ligand (demonstrated as the Truck GPS set to find a specific Target)
- Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
- Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
- Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
- Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).
To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTSTab.
Education
Learn More About How Radiation Works
We know radiation can be scary, but we want to show you how radiation isn't all that it seems and how you interact with radiation every day!
Learn More About How Theranostics Work
Theranostics is a two-pronged approach to diagnosing and treating cancers through the use of radiotracers.
Learn More About Clinical Trials
A clinical trial is a research effort that aims to evaluate the effects of an intervention on the development of a disease.